.Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B02B_VitaminKAndOtherHemostatics.B02BD10_VonWillebrandFactor.VonWillebrandFactor .Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B02B_VitaminKAndOtherHemostatics.B02BD10_VonWillebrandFactor.VonWillebrandFactor| name: | VonWillebrandFactor | |
| ATC code: | B02BD10 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 50 | mg |
| volume of distribution: | 0.047 | L |
| clearance: | 0.041 | L/h/kg |
| other parameters in model implementation | ||
Von Willebrand factor (vWF) is a large multimeric glycoprotein important in hemostasis. It mediates platelet adhesion to sites of vascular injury and serves as a carrier protein for coagulation factor VIII. Plasma-derived and recombinant vWF products are used primarily in the treatment and prevention of bleeding episodes in patients with von Willebrand disease, a congenital or acquired bleeding disorder. vWF is an approved drug for clinical use today.
Pharmacokinetics in adults with severe von Willebrand disease following intravenous administration of plasma-derived von Willebrand factor concentrate (e.g., Wilate), using a one-compartment model.
Nestorov, I, et al., & Rogge, M (2015). Population pharmacokinetics of recombinant factor VIII Fc fusion protein. Clinical pharmacology in drug development 4(3) 163–174. DOI:10.1002/cpdd.167 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27140796
Gritsch, H, et al., & Turecek, PL (2022). Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease. Journal of blood medicine 13 649–662. DOI:10.2147/JBM.S377126 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36405429
Bauer, A, et al., & Wolfsegger, M (2023). Pharmacokinetic-Pharmacodynamic Comparison of Recombinant and Plasma-Derived von Willebrand Factor in Patients with von Willebrand Disease Type 3. Journal of blood medicine 14 399–411. DOI:10.2147/JBM.S395845 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37332615